BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2007

View Archived Issues

Novel treatment options for cancer outlined in recent patent literature

Read More

New agents for psychopharmacologic disorders described in recent patents

Read More

Clera patent discloses novel imaging agents for Parkinson's disease

Read More

AstraZeneca announces second quarter 2007 results

Read More

Novavax initiates clinical trial for VLP-based influenza vaccine

Read More

Ovation begins clinical trial of i.v. carbamazepine for epilepsy

Read More

Valeant completes enrollment of first retigabine pivotal phase III study

Read More

Orphan drug designation of LX-211 recommended by EMEA committee

Read More

Mecamylamine augmentation for the treatment of depression

Read More

First-in-man study of a compound targeting CENP-E

Read More

Ovarian cancer vaccine stimulates immune response in a phase I trial

Read More

MacroGenics initiates three clinical trials with teplizumab in type 1 diabetes

Read More

Univ. Birmingham selects Eden Biodesign to develop and produce novel autoimmune disease drug

Read More

ORG-26576 enhanced AMPA receptor function and increased working memory in animal studies

Read More

Genta and Emisphere submit IND for oral G-4544 formulation

Read More

Tobira completes Series A financing and licenses rights to Takeda anti-HIV compounds

Read More

Nuvelo reduces workforce and readjusts development programs

Read More

Rosetta Genomics and Ben Gurion University to collaborate on microRNA-based applications

Read More

Advanced Cell Technology and Mytogen enter merger agreement

Read More

OncoGenex begins enrollment for OGX-427 phase I trial for cancer

Read More

Enzon enrolls patients in PEG-SN38 phase I study for solid tumors or lymphoma

Read More

MedImmune begins phase IIa trial of MEDI-528 for asthma

Read More

Rheoscience and Dr. Reddy's begin phase III study of balaglitazone

Read More

New HIV Tat vaccine induces humoral and cell-mediated immune responses in mice

Read More

Interim results show improved lipid profiles in HIV patients treated with boosted Invirase

Read More

FDA approves Indevus's Sanctura XR for once-daily treatment of OAB

Read More

Health Canada approves GW and Bayer's Sativex for cancer pain

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing